SLS draws attention on RVMD's pancreatic cancer drug approval; short-term focus on AML

SLS -4.55%

1. 1Cellular (SLS) sees retail interest as FDA approves Revolution Medicines' (RVMD) RAS(ON) for advanced pancreatic cancer
2. 2SLS009 has yet to enter human trials for pancreatic cancer; mid-stage data for newly diagnosed AML slated for Q4 this year
3. 3Short-term focus is on AML; GPS REGAL has completed 78 of the 80 events needed as of May, with analysis pending

Source Barrons.com +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →